Rocket Lab USA Inc vs Smith & Nephew plc — how do they compare? Rocket Lab USA Inc trades at $69.31 (market cap $43.19B), while Smith & Nephew plc trades at $29.95 (market cap $12.71B). The key difference: Rocket Lab USA Inc is far larger — about 3.4× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.59% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals.
| RKLB | SNN | |
|---|---|---|
Market Cap | $43.19B | $12.71B |
Sector | Technology | Health |
52-Week High | $150.23 | $38.70 |
52-Week Low | $39.48 | $28.73 |
Enterprise Value | $41.94B | $15.48B |
Dividend Yield | — | 2.59% |
Signals from Pluang's Aura AI — not financial advice
Rocket Lab (RKLB) trades at $65.74, down 2.78% on the day, with a bearish technical signal despite oscillators suggesting oversold conditions. The company reported a net loss of $198.21 million in 2025, though revenue grew to $601.80 million. Recent positive news includes a $266 million defense contract awarded on July 21, 2026, per Benzinga, providing a near-term catalyst amid broader sector volatility.
The outlook remains high-risk with negative profitability but strong analyst support; 75% recommend Buy with a $116.90 consensus target. Key risks include execution delays on the Neutron rocket and intense competition. Upside depends on contract execution and path to profitability, while downside stems from cash burn and market sentiment shifts.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →